Premium Nahrungsergänzungsmittel | artgerecht

Bacteriocin – Definition, Mechanism and Medical Use

Bacteriocins are antimicrobial peptides produced by bacteria to kill or inhibit competing bacterial strains. They are regarded as a promising alternative to conventional antibiotics.

Regular tips about health Regular tips about health

Things worth knowing about "Bacteriocin"

Bacteriocins are antimicrobial peptides produced by bacteria to kill or inhibit competing bacterial strains. They are regarded as a promising alternative to conventional antibiotics.

What Are Bacteriocins?

Bacteriocins are ribosomally synthesized antimicrobial peptides or proteins produced and secreted by bacteria. Their primary function is to kill or inhibit the growth of closely related or competing bacterial strains. Bacteriocins are found in both gram-negative and gram-positive bacteria and play a significant role in microbial competition within ecosystems such as the human gut microbiome.

Mechanism of Action

Bacteriocins exert their antimicrobial effects through several distinct molecular mechanisms:

Pore formation in the cell membrane: Many bacteriocins, such as nisin, create pores in the bacterial cell membrane, causing the leakage of ions and essential molecules, ultimately leading to cell death.
Inhibition of cell wall synthesis: Certain bacteriocins interfere with peptidoglycan biosynthesis, a critical component of the bacterial cell wall.
Degradation of DNA or RNA: Some bacteriocins, known as nucleases, destroy the genetic material of the target cell.
Inhibition of protein biosynthesis: Other bacteriocins block ribosomal processes, preventing protein synthesis in target bacteria.

Classification

Bacteriocins are classified into several groups based on their biochemical characteristics:

Class I (Lantibiotics): Small, heat-stable peptides containing unusual amino acids, such as nisin. Produced by gram-positive bacteria.
Class II: Small, heat-stable, non-lanthipeptide antimicrobial peptides, further divided into subclasses (IIa, IIb, IIc).
Class III: Large, heat-labile proteins with enzymatic activity, such as bacteriolysins.
Bacteriocins of gram-negative bacteria: Colicins and microcins, produced by Escherichia coli and related species.

Medical and Clinical Relevance

In light of the global rise of antibiotic resistance, bacteriocins are gaining considerable attention as potential therapeutic alternatives. Key areas of application include:

Treatment of multidrug-resistant pathogens: Bacteriocins such as nisin show activity against methicillin-resistant Staphylococcus aureus (MRSA) and other clinically problematic organisms.
Food safety: Nisin is approved as a food additive (E234) and is widely used as a preservative in cheese and other dairy products.
Probiotics and gut health: Bacteriocin-producing lactic acid bacteria, such as Lactobacillus species, play an important role in maintaining a healthy gut microbiota by displacing pathogenic bacteria.
Wound care and dermatology: Topical applications of bacteriocins are being investigated as a strategy to combat resistant bacterial infections in wounds.

Advantages Over Conventional Antibiotics

Bacteriocins offer several potential advantages compared to traditional antibiotics:

Narrow activity spectra: they target specific bacterial strains without broadly disrupting the entire microbiota.
Lower potential for resistance development compared to some broad-spectrum antibiotics.
Biodegradability by proteases present in the human body.
Good tolerability when applied locally or topically.

Current Research and Outlook

Research into bacteriocins is advancing rapidly. Numerous clinical and preclinical studies are investigating their potential as therapeutics, food preservatives, and probiotic components. Genetic engineering techniques are also enabling the targeted optimization of bacteriocins in terms of stability, efficacy, and spectrum of activity. The World Health Organization (WHO) has identified the development of novel antimicrobial agents as a global health priority, and bacteriocins represent a particularly promising avenue of research in this context.

References

Cotter, P. D., Ross, R. P., Hill, C. (2013). Bacteriocins - a viable alternative to antibiotics? Nature Reviews Microbiology, 11(2), 95-105.
World Health Organization (WHO) (2017). Global priority list of antibiotic-resistant bacteria. WHO Press, Geneva.
Alvarez-Sieiro, P. et al. (2016). Bacteriocins of lactic acid bacteria: extending the family. Applied Microbiology and Biotechnology, 100(7), 2939-2951.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.